Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. Juli 2025 13:13 ET | Quelle: Quetzal Therapeutics

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.
17. Juni 2021 08:30 ET | Quelle: HelixBind

HelixBind Awarded $3MM NIH Grant to Support Testing of Its RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis

BOXBOROUGH, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
24. August 2020 11:47 ET | Quelle: HelixBind

FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test

BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
16. Juli 2020 12:01 ET | Quelle: HelixBind

HelixBind Awarded $3MM Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease

BOXBOROUGH, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for patients afflicted with invasive microbial infections,...
10. Juni 2020 10:29 ET | Quelle: HelixBind

HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections

BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...